[go: up one dir, main page]

UY32663A - Proteinas de union a antigeno - Google Patents

Proteinas de union a antigeno

Info

Publication number
UY32663A
UY32663A UY0001032663A UY32663A UY32663A UY 32663 A UY32663 A UY 32663A UY 0001032663 A UY0001032663 A UY 0001032663A UY 32663 A UY32663 A UY 32663A UY 32663 A UY32663 A UY 32663A
Authority
UY
Uruguay
Prior art keywords
antigen
binding
proteins
union
hgf
Prior art date
Application number
UY0001032663A
Other languages
English (en)
Inventor
Paul Andrew Hamblin
Neil James Clarke
Susannah Karen Ford
Martin Stephen
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of UY32663A publication Critical patent/UY32663A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención se refiere a combinaciones de antagonistas de HGF con antagonistas de VEGF y proporciona proteínas de unión a anfígeno que se unen a HGF, que comprenden un armazón proteico que está unido a uno o más dominios de unión a epítopo, en el que la proteína de unión a antígeno tiene al menos dos sitios de unión a antígeno, al menos uno de los cuales procede de un dominio VH/VL apareado, a procedimientos de fabricar dichos constructos y a usos de los mismos.
UY0001032663A 2009-05-28 2010-05-26 Proteinas de union a antigeno UY32663A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18188109P 2009-05-28 2009-05-28

Publications (1)

Publication Number Publication Date
UY32663A true UY32663A (es) 2010-12-31

Family

ID=42320696

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032663A UY32663A (es) 2009-05-28 2010-05-26 Proteinas de union a antigeno

Country Status (8)

Country Link
US (1) US20120177651A1 (es)
EP (1) EP2435478A1 (es)
JP (1) JP2012527876A (es)
AR (1) AR078046A1 (es)
CA (1) CA2763488A1 (es)
TW (1) TW201106971A (es)
UY (1) UY32663A (es)
WO (1) WO2010136482A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2643351A1 (en) * 2010-11-24 2013-10-02 Glaxo Group Limited Multispecific antigen binding proteins targeting hgf
WO2012104227A1 (en) 2011-02-02 2012-08-09 Glaxo Group Limited Novel antigen binding proteins
WO2013110531A1 (en) * 2012-01-23 2013-08-01 Ablynx Nv Sequences directed against hepatocyte growth factor (hgf) and polypeptides comprising the same for the treatment of cancers and/or tumors
KR102049990B1 (ko) * 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
CN105358699A (zh) * 2013-04-29 2016-02-24 阿格罗塞文公司 包含结合至鞘脂的抗体的农用化学组合物
WO2014191574A1 (en) 2013-05-31 2014-12-04 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor
KR102236367B1 (ko) * 2013-07-26 2021-04-05 삼성전자주식회사 DARPin을 포함하는 이중 특이 키메라 단백질
CN106459193A (zh) * 2014-04-17 2017-02-22 特瑞克隆艾迪福公司 用于中和血管内皮生长因子的重组单株抗体vNAR

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008512352A (ja) * 2004-07-17 2008-04-24 イムクローン システムズ インコーポレイティド 新規な四価の二重特異性抗体
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
CA2646508A1 (en) * 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
ES2622460T3 (es) * 2007-09-26 2017-07-06 Ucb Biopharma Sprl Fusiones de anticuerpos con doble especificidad

Also Published As

Publication number Publication date
EP2435478A1 (en) 2012-04-04
CA2763488A1 (en) 2010-12-02
US20120177651A1 (en) 2012-07-12
AR078046A1 (es) 2011-10-12
TW201106971A (en) 2011-03-01
WO2010136482A1 (en) 2010-12-02
JP2012527876A (ja) 2012-11-12

Similar Documents

Publication Publication Date Title
UY32663A (es) Proteinas de union a antigeno
UY32501A (es) Anticuerpo antagonista específico para el heterodímero alfa4-beta7
EA201000704A1 (ru) Антигенсвязывающие конструкции
EA201390611A1 (ru) Мультиспецифические антигенсвязывающие белки, направленные на hgf
EP3459597A4 (en) ANTI-CTLA4 SINGLE DOMAIN ANTIBODIES AND PROTEIN DERIVED THEREFROM
MX2022002959A (es) Anticuerpos anti-tigit y metodos de uso.
PT4063397T (pt) Recetores de antigénios quiméricos com base em anticorpos de domínio único e métodos de utilização dos mesmos
BR112014008382A2 (pt) anticorpo especificamente ligando a epítope no domínio sema do c-met
CL2016003346A1 (es) Anticuerpos anti-tau humanizados
MX375020B (es) Anticuerpos anti-alfa-sinucleina y métodos de uso.
MX380520B (es) Anticuerpos receptores de antitransferina y métodos de uso.
BR112016022841A2 (pt) cadeia j modificada
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
ECSP13013001A (es) Moléculas de unión biespecíficas que se unen a vegf y ang2.
CO7151527A2 (es) Anticuerpos anti-cd79 b e inmunoconjugados
EA201401065A1 (ru) Ang2-связывающие молекулы
MX2023000738A (es) Proteinas de union a antigeno que activan el receptor de leptina.
AR090909A1 (es) Antagonistas de st2l y metodos de uso
MX2015017331A (es) Anticuerpos anti fc similar a receptor 5 (fcrh5).
AR088403A1 (es) Anticuerpo de union a multiples antigenos estable
AR077111A1 (es) Proteinas biespecificas tetravalentes de union a antigeno
DK2560993T3 (da) Heterodimeric antibody fc-containing proteins and methods for production thereof
EA201692539A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
EA201171494A1 (ru) Миметики белка smac
EA201691027A1 (ru) Модуляторы aplnr и их применение

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20130125